New ways to treat cancer by disrupting DNA repair
Novel DNA damage response therapeutics targeting replication protein A
This research explores a new medicine that helps stop cancer cells from repairing their DNA, aiming to develop better treatments for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11129730 on NIH RePORTER |
What this research studies
Cancer cells often have problems with their DNA, and this research looks for ways to use those weaknesses against them. We are focusing on a specific protein called RPA, which cancer cells rely on to repair their DNA and survive. By developing a new drug that blocks RPA, we hope to make cancer cells unable to fix their DNA damage, leading to their death. This approach could offer a new strategy to fight various types of cancer.
Who could benefit from this research
Good fit: Future patients with various types of cancer, particularly those where DNA repair pathways are already compromised, could potentially benefit from therapies developed from this research.
Not a fit: Patients whose cancers do not rely on the specific DNA repair pathway targeted by this research may not receive direct benefit from this particular approach.
Why it matters
Potential benefit: If successful, this work could lead to a new class of drugs that specifically target cancer cells by disrupting their DNA repair mechanisms, potentially offering more effective treatments.
How similar studies have performed: Other drugs, like PARP inhibitors, have shown success by targeting similar DNA repair pathways in cancer, suggesting this approach has a strong foundation.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Turchi, John J. — Indiana University Indianapolis
- Study coordinator: Turchi, John J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.